MedPage Today12 分钟
FDA Pauses Obesity Drug Study; Diabetic Eye Therapy OK'd; 'Misleading' Super Bowl Ad
Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...